
Episode #12
Why Patent Cliffs Are Fueling Pharmaceutical M&A
Pharma M&A is on track to exceed $160 billion this year, its highest level since before the pandemic. With $300 billion of revenue exposed to patent expirations over the next five years, drugmakers are turning to acquisitions to replenish pipelines and replace lost revenue. GLP-1 weight-loss drugs, along with oncology and neuroscience, key areas driving deal activity. Host: Chandra Ghosal, Vice President, Moody’s Ratings Guest: Michael Weinstein, Executive Director, Moody’s Ratings Related Research: Stable outlook reflects moderate earnings growth and reduced US policy risks , 1 June 2026 © 2026 Moody’s Corporation and/or its licensors and affiliates. All rights reserved. Go to www.moodys.com/pages/globaldisclaimer.aspx for complete legal terms and conditions governing use of Moody’s information made available in this video. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

